Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.97
NAS:ARRY's Cash to Debt is ranked lower than
81% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. NAS:ARRY: 0.97 )
Ranked among companies with meaningful Cash to Debt only.
NAS:ARRY' s Cash to Debt Range Over the Past 10 Years
Min: 0.49  Med: 1.63 Max: No Debt
Current: 0.97
Equity to Asset -0.23
NAS:ARRY's Equity to Asset is ranked lower than
94% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:ARRY: -0.23 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ARRY' s Equity to Asset Range Over the Past 10 Years
Min: -1.46  Med: 0.3 Max: 0.93
Current: -0.23
-1.46
0.93
F-Score: 4
Z-Score: -5.16
M-Score: 0.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -59.62
NAS:ARRY's Operating margin (%) is ranked higher than
54% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NAS:ARRY: -59.62 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ARRY' s Operating margin (%) Range Over the Past 10 Years
Min: -410.11  Med: -89.25 Max: 6.34
Current: -59.62
-410.11
6.34
Net-margin (%) -67.33
NAS:ARRY's Net-margin (%) is ranked higher than
53% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. NAS:ARRY: -67.33 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ARRY' s Net-margin (%) Range Over the Past 10 Years
Min: -511.63  Med: -116.55 Max: 18.05
Current: -67.33
-511.63
18.05
ROE (%) -2333.48
NAS:ARRY's ROE (%) is ranked lower than
99% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NAS:ARRY: -2333.48 )
Ranked among companies with meaningful ROE (%) only.
NAS:ARRY' s ROE (%) Range Over the Past 10 Years
Min: -3933.07  Med: -97.52 Max: 110.67
Current: -2333.48
-3933.07
110.67
ROA (%) -48.87
NAS:ARRY's ROA (%) is ranked lower than
68% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. NAS:ARRY: -48.87 )
Ranked among companies with meaningful ROA (%) only.
NAS:ARRY' s ROA (%) Range Over the Past 10 Years
Min: -99.03  Med: -50.67 Max: 5.6
Current: -48.87
-99.03
5.6
ROC (Joel Greenblatt) (%) -705.67
NAS:ARRY's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. NAS:ARRY: -705.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ARRY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1397.54  Med: -273.72 Max: 297.05
Current: -705.67
-1397.54
297.05
Revenue Growth (3Y)(%) 14.30
NAS:ARRY's Revenue Growth (3Y)(%) is ranked higher than
66% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. NAS:ARRY: 14.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ARRY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -35.9  Med: -2.7 Max: 39.8
Current: 14.3
-35.9
39.8
EBITDA Growth (3Y)(%) 9.40
NAS:ARRY's EBITDA Growth (3Y)(%) is ranked higher than
62% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:ARRY: 9.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:ARRY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.3  Med: 0.7 Max: 105.1
Current: 9.4
-66.3
105.1
EPS Growth (3Y)(%) 4.50
NAS:ARRY's EPS Growth (3Y)(%) is ranked higher than
60% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. NAS:ARRY: 4.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:ARRY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.4  Med: 0.8 Max: 55.7
Current: 4.5
-50.4
55.7
» NAS:ARRY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ARRY Guru Trades in Q3 2015

Paul Tudor Jones 11,500 sh (New)
Ken Fisher 135,695 sh (New)
Jim Simons 929,428 sh (+14.46%)
» More
Q4 2015

ARRY Guru Trades in Q4 2015

Steven Cohen 952,200 sh (New)
Paul Tudor Jones 107,347 sh (+833.45%)
Jim Simons 3,210,394 sh (+245.42%)
Ken Fisher 135,695 sh (unchged)
» More
Q1 2016

ARRY Guru Trades in Q1 2016

Ken Fisher 135,695 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Jim Simons 2,154,652 sh (-32.89%)
» More
Q2 2016

ARRY Guru Trades in Q2 2016

Ken Fisher 135,695 sh (unchged)
Jim Simons 17,452 sh (-99.19%)
» More
» Details

Insider Trades

Latest Guru Trades with ARRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:EDIT, NAS:ACRS, NAS:OTIC, NAS:MCRB, NAS:RETA, NAS:AMRN, NAS:ADAP, NAS:KERX, NAS:ENTA, NAS:BLCM, NAS:RVNC, NAS:CYNA, NAS:NERV, NAS:EPZM, NAS:ASND, NAS:FLML, NAS:CTMX, NAS:PDLI, NAS:CLCD, NAS:LJPC » details
Traded in other countries:AR2.Germany,
Array BioPharma Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.

Array BioPharma Inc was incorporated in Delaware on February 6, 1998. It is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The Company's proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. In addition, pharmaceutical and biotechnology companies partner with the Company to discover and develop drug candidates across various therapeutic areas. The Company's proprietary clinical programs include three cancer drugs, binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (partnered with AstraZeneca. The Company's internal drug discovery programs include inhibitors that target Trk receptors for the treatment of oncology and other indications. The Company competes with companies that are engaged in the research and discovery, licensing, development and commercialization of drug candidates, including large pharmaceutical companies with internal discovery and development functions, biotech companies with competing products in the therapeutic areas it is targeting and contract research organizations that perform many of the functions it performs under its collaborations. The Company is subject to substantial regulation by governmental agencies in the U.S. and other countries.

Ratios

vs
industry
vs
history
P/S 6.47
ARRY's P/S is ranked higher than
76% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. ARRY: 6.47 )
Ranked among companies with meaningful P/S only.
ARRY' s P/S Range Over the Past 10 Years
Min: 1.43  Med: 6.82 Max: 24.26
Current: 6.47
1.43
24.26
Current Ratio 2.96
ARRY's Current Ratio is ranked lower than
64% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. ARRY: 2.96 )
Ranked among companies with meaningful Current Ratio only.
ARRY' s Current Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.93 Max: 7.45
Current: 2.96
0.89
7.45
Quick Ratio 2.96
ARRY's Quick Ratio is ranked lower than
61% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. ARRY: 2.96 )
Ranked among companies with meaningful Quick Ratio only.
ARRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.93 Max: 5.97
Current: 2.96
0.89
5.97
Days Sales Outstanding 104.04
ARRY's Days Sales Outstanding is ranked lower than
74% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. ARRY: 104.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.06  Med: 47.09 Max: 497.21
Current: 104.04
2.06
497.21
Days Payable 159.87
ARRY's Days Payable is ranked higher than
79% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. ARRY: 159.87 )
Ranked among companies with meaningful Days Payable only.
ARRY' s Days Payable Range Over the Past 10 Years
Min: 37.58  Med: 76.12 Max: 159.87
Current: 159.87
37.58
159.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.10
ARRY's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. ARRY: -7.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARRY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -111.3  Med: -11.8 Max: -4.2
Current: -7.1
-111.3
-4.2

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.95
ARRY's Price/Median PS Value is ranked higher than
80% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. ARRY: 0.95 )
Ranked among companies with meaningful Price/Median PS Value only.
ARRY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.25  Med: 0.92 Max: 2.83
Current: 0.95
0.25
2.83
Earnings Yield (Greenblatt) (%) -9.06
ARRY's Earnings Yield (Greenblatt) (%) is ranked lower than
66% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. ARRY: -9.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARRY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -15.4  Med: 2.25 Max: 5.1
Current: -9.06
-15.4
5.1

More Statistics

Revenue (TTM) (Mil) $137.9
EPS (TTM) $ -0.66
Beta1.14
Short Percentage of Float13.89%
52-Week Range $2.39 - 7.27
Shares Outstanding (Mil)145.02
» More Articles for NAS:ARRY

Headlines

Articles On GuruFocus.com
Screen: Stocks With Estimated Revenue Up 5% - January Jan 18 2016 
Insider Buys Round-up: Tenet Healthcare and Sprint Corp Aug 14 2015 
Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,310 Shares Mar 16 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,403 Shares Feb 11 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,272 Shares Jan 13 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,256 Shares Dec 10 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,220 Shares Nov 12 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,225 Shares Oct 13 2010 

More From Other Websites
2:40 am Array Biopharma prices offering of 18.4 mln shares of its common stock at $6.25 per share Sep 29 2016
Array BioPharma Reports Positive Results (ARRY) Sep 28 2016
ARRAY BIOPHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Sep 28 2016
Why Wells Fargo, Select Comfort, Array Biopharma, American Express, and More Are Trending Sep 28 2016
Array BioPharma Announces Pricing of Public Offering of Common Stock Sep 27 2016
Array BioPharma Announces Pricing of Public Offering of Common Stock Sep 27 2016
Array BioPharma Announces Proposed Public Offering of Common Stock Sep 27 2016
Array BioPharma Announces Proposed Public Offering of Common Stock Sep 27 2016
ProNAi Therapeutics Inc. (DNAI), Ballard Power Systems Inc. (USA) (BLDP) & More: Major Hype... Sep 27 2016
Array BioPharma (ARRY) Stock Up, JPMorgan Raises Price Target on Drug Success Sep 27 2016
Momentum Carries Lululemon Lower, Pushes Biotech Names Higher Sep 27 2016
ETF’s with exposure to Array BioPharma, Inc. : September 27, 2016 Sep 27 2016
Array (ARRY) Hits 52-Week High on Positive Phase III Data Sep 27 2016
Top Analyst Upgrades and Downgrades: CBOE, Comcast, GW Pharma, Hormel, Vonage, Wells Fargo and Many... Sep 27 2016
Why Investors Are Buzzing About Yum, Twitter, GM, RetailMeNot, and Array Biopharma Today Sep 26 2016
Array Biopharma Shares Soar on Melanoma Trial’s Early Results Sep 26 2016
Array BioPharma (ARRY) Stock Soars on Drug Success, Piper Jaffray Ups Price Target Sep 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)